Overcome Cancer Cell Drug Resistance Using Natural Products.

Pu Wang, Hua Li Yang, Ying Juan Yang, Lan Wang, Shao Chin Lee
Author Information
  1. Pu Wang: School of Life Sciences, Shanxi University, Taiyuan, Shanxi 030006, China.
  2. Hua Li Yang: School of Life Sciences, Shanxi University, Taiyuan, Shanxi 030006, China.
  3. Ying Juan Yang: School of Life Sciences, Shanxi University, Taiyuan, Shanxi 030006, China.
  4. Lan Wang: School of Life Sciences, Shanxi University, Taiyuan, Shanxi 030006, China.
  5. Shao Chin Lee: School of Life Sciences, Shanxi University, Taiyuan, Shanxi 030006, China.

Abstract

Chemotherapy is one of the major treatment methods for cancer. However, failure in chemotherapy is not uncommon, mainly due to dose-limiting toxicity associated with drug resistance. Management of drug resistance is important towards successful chemotherapy. There are many reports in the Chinese literature that natural products can overcome cancer cell drug resistance, which deserve sharing with scientific and industrial communities. We summarized the reports into four categories: (1) in vitro studies using cell line models; (2) serum pharmacology; (3) in vivo studies using animal models; and (4) clinical studies. Fourteen single compounds were reported to have antidrug resistance activity for the first time. In vitro, compounds were able to overcome drug resistance at nontoxic or subtoxic concentrations, in a dose-dependent manner, by inhibiting drug transporters, cell detoxification capacity, or cell apoptosis sensitivity. Studies in vivo showed that single compounds, herbal extract, and formulas had potent antidrug resistance activities. Importantly, many single compounds, herbal extracts, and formulas have been used clinically to treat various diseases including cancer. The review provides comprehensive data on use of natural compounds to overcome cancer cell drug resistance in China, which may facilitate the therapeutic development of natural products for clinical management of cancer drug resistance.

References

  1. Pharmacogenomics. 2008 Jan;9(1):105-27 [PMID: 18154452]
  2. Cancer Lett. 2006 Apr 8;235(1):84-92 [PMID: 15990223]
  3. Zhonghua Xue Ye Xue Za Zhi. 2006 Apr;27(4):254-8 [PMID: 16875558]
  4. Chin J Dig Dis. 2005;6(2):82-6 [PMID: 15904426]
  5. Oncol Rep. 2014 Feb;31(2):858-66 [PMID: 24284783]
  6. J Ethnopharmacol. 1987 Sep-Oct;21(1):45-53 [PMID: 3695555]
  7. Biochem Pharmacol. 2012 Apr 15;83(8):1005-12 [PMID: 22138445]
  8. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Jan;28(1):17-9 [PMID: 18418962]
  9. Mar Drugs. 2014 Jun 27;12 (7):3818-37 [PMID: 24979269]
  10. J Exp Clin Cancer Res. 2014 Apr 28;33:37 [PMID: 24775603]
  11. Cancers (Basel). 2014 Sep 05;6(3):1769-92 [PMID: 25198391]
  12. Cancer Lett. 2014 Jun 1;347(2):159-66 [PMID: 24657660]
  13. Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79 [PMID: 24120656]
  14. Gynecol Oncol. 1998 Aug;70(2):176-82 [PMID: 9740686]
  15. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003 Dec;11(6):604-8 [PMID: 14706144]
  16. Zhonghua Xue Ye Xue Za Zhi. 2010 Jun;31(6):381-4 [PMID: 21122352]
  17. World J Surg Oncol. 2014 Oct 11;12:307 [PMID: 25304659]
  18. Oncol Rep. 2013 Sep;30(3):1119-28 [PMID: 23765060]
  19. Zhongguo Zhong Yao Za Zhi. 2005 Feb;30(4):280-3 [PMID: 15724407]
  20. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70 [PMID: 9861027]
  21. Br J Cancer. 1993 Aug;68(2):235-9 [PMID: 8347477]
  22. Pharmacogenet Genomics. 2014 Jul;24(7):340-7 [PMID: 24842074]
  23. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):756-61 [PMID: 17708798]
  24. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1306-10 [PMID: 25338578]
  25. Curr Pharm Des. 2013;19(40):7126-40 [PMID: 23829373]
  26. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005 Oct;30(5):558-61 [PMID: 16320588]
  27. Biochim Biophys Acta. 2011 Jun;1807(6):735-45 [PMID: 21453675]
  28. Nutr Cancer. 2015 ;67(3):411-23 [PMID: 25649862]
  29. Mol Pharm. 2012 Nov 5;9(11):3147-59 [PMID: 23046348]
  30. PLoS One. 2013 Jun 24;8(6):e67589 [PMID: 23826324]
  31. Front Chem. 2014 May 01;2:20 [PMID: 24822174]
  32. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):884-9 [PMID: 21867607]
  33. Zhonghua Zhong Liu Za Zhi. 2004 May;26(5):268-70 [PMID: 15312359]
  34. Mar Drugs. 2015 Apr 14;13(4):2267-86 [PMID: 25874923]
  35. Nat Rev Drug Discov. 2011 Jun 24;10 (7):507-19 [PMID: 21701501]
  36. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Dec;21(6):1413-22 [PMID: 24370022]
  37. Zhonghua Gan Zang Bing Za Zhi. 2004 Oct;12 (10 ):597-600 [PMID: 15504289]
  38. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Feb;33(1):45-50 [PMID: 21375937]
  39. Zhong Yao Cai. 2004 Nov;27(11):838-40 [PMID: 15810592]
  40. Drug Discov Today. 2014 Oct;19(10):1547-62 [PMID: 24819719]

Word Cloud

Created with Highcharts 10.0.0resistancedrugcancercellcompoundsnaturalovercomestudiessinglechemotherapymanyreportsproductsvitrousingmodelsvivoclinicalantidrugherbalformulasChemotherapyonemajortreatmentmethodsHoweverfailureuncommonmainlyduedose-limitingtoxicityassociatedManagementimportanttowardssuccessfulChineseliteraturecandeservesharingscientificindustrialcommunitiessummarizedfourcategories:1line2serumpharmacology3animal4Fourteenreportedactivityfirsttimeablenontoxicsubtoxicconcentrationsdose-dependentmannerinhibitingtransportersdetoxificationcapacityapoptosissensitivityStudiesshowedextractpotentactivitiesImportantlyextractsusedclinicallytreatvariousdiseasesincludingreviewprovidescomprehensivedatauseChinamayfacilitatetherapeuticdevelopmentmanagementOvercomeCancerCellDrugResistanceUsingNaturalProducts

Similar Articles

Cited By